Prof. Dr. Steven A Johnsen
@profjohnsen.bsky.social
Pancreatic cancer researcher investigating transcription & epigenetic regulation of cell identity. Assoc. Editor at @nar-cancer-editor.bsky.social
Congrats to Tom Ekstrom on this insightful new review in NAR Cancer! Excited to see how our upcoming experiments will test the molecular amnesia hypothesis — could reveal key links between #enhancer-proximal #pausing, #generegulation & tumor identity.
👉 academic.oup.com/narcancer/ar...
👉 academic.oup.com/narcancer/ar...
Validate User
academic.oup.com
November 12, 2025 at 5:41 PM
Congrats to Tom Ekstrom on this insightful new review in NAR Cancer! Excited to see how our upcoming experiments will test the molecular amnesia hypothesis — could reveal key links between #enhancer-proximal #pausing, #generegulation & tumor identity.
👉 academic.oup.com/narcancer/ar...
👉 academic.oup.com/narcancer/ar...
Super happy to see this commentary in @Gut_BMJ about our recent work!!!
Truly one of the most exciting and rewarding projects of my career. So happy to have worked with Tom Ekstrom on this exciting project!
#FuturePI
#ProudMentor
#BoschStiftung
doi.org/10.1136/gutj...
Truly one of the most exciting and rewarding projects of my career. So happy to have worked with Tom Ekstrom on this exciting project!
#FuturePI
#ProudMentor
#BoschStiftung
doi.org/10.1136/gutj...
Distinct gene expression mechanisms in classical and basal PDAC subtypes
Pancreatic ductal adenocarcinoma (PDAC) represents approximately 90% of all malignant tumours in the pancreas, and it is one of the deadliest human diseases. It has a 5-year survival rate of less than...
doi.org
April 24, 2025 at 10:23 AM
Super happy to see this commentary in @Gut_BMJ about our recent work!!!
Truly one of the most exciting and rewarding projects of my career. So happy to have worked with Tom Ekstrom on this exciting project!
#FuturePI
#ProudMentor
#BoschStiftung
doi.org/10.1136/gutj...
Truly one of the most exciting and rewarding projects of my career. So happy to have worked with Tom Ekstrom on this exciting project!
#FuturePI
#ProudMentor
#BoschStiftung
doi.org/10.1136/gutj...
Mayo has played such a special & central role in my life & my career! Since my first visit to the @mayoclinic.org when interviewing for graduate school in 1999 till 20 years later becoming a staff member and Professor in 2019, this place remains in my blood.
March 17, 2025 at 3:23 PM
Mayo has played such a special & central role in my life & my career! Since my first visit to the @mayoclinic.org when interviewing for graduate school in 1999 till 20 years later becoming a staff member and Professor in 2019, this place remains in my blood.
Super excited to be back on board as Associate Editor at
@nar-cancer-editor.bsky.social
NAR Cancer is a great place to bring your cancer research papers, where you can be ensured a quality peer review at a top notch academic publisher (with full open access!).
@nar-cancer-editor.bsky.social
NAR Cancer is a great place to bring your cancer research papers, where you can be ensured a quality peer review at a top notch academic publisher (with full open access!).
March 11, 2025 at 10:35 PM
Super excited to be back on board as Associate Editor at
@nar-cancer-editor.bsky.social
NAR Cancer is a great place to bring your cancer research papers, where you can be ensured a quality peer review at a top notch academic publisher (with full open access!).
@nar-cancer-editor.bsky.social
NAR Cancer is a great place to bring your cancer research papers, where you can be ensured a quality peer review at a top notch academic publisher (with full open access!).
Very excited about our recent paper describing differential mechanistic roles of the #mastertranscriptionfactors #GATA6 and #dNp63 in controlling #pancreaticcancer molecular subtype identity.
bit.ly/3Q1wUzF
#BoschStiftung
#PDAC
#CancerResearch
bit.ly/3Q1wUzF
#BoschStiftung
#PDAC
#CancerResearch
Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a 5-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master trans...
bit.ly
March 6, 2025 at 1:51 PM
Very excited about our recent paper describing differential mechanistic roles of the #mastertranscriptionfactors #GATA6 and #dNp63 in controlling #pancreaticcancer molecular subtype identity.
bit.ly/3Q1wUzF
#BoschStiftung
#PDAC
#CancerResearch
bit.ly/3Q1wUzF
#BoschStiftung
#PDAC
#CancerResearch